Factors Predicting Chemotherapy Induced-Peripheral Neuropathy in Cancer Patients Treated with Taxane and Platinum-Based Chemotherapy
Article Sidebar
Main Article Content
Abstract
Purpose: To study the predictive power of age, BMI change, number of taxane or platinum-based chemotherapy received, cumulative dose, negative emotional states, and physical activity on chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients treated with taxane and platinum-based chemotherapy.
Design: A cross-sectional study with predictive correlational design.
Methods: The sample consisted of 155 patients who were diagnosed with non-hematological cancer and treated with taxane or platinum-based chemotherapy drugs in the last cycle of chemotherapy at the inpatient and outpatient chemotherapy units of a tertiary hospital in Bangkok, Thailand. Data were collected using the demographic data and medical record form questionnaires, the Depression Anxiety Stress Scale-21, the Global Physical Activity Questionnaire, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy. Descriptive statistics and stepwise multiple regression were used for the data analysis.
Main findings: Significant predictors of CIPN among cancer patients treated with taxane and platinum-based chemotherapy included negative emotional states (β = .38, p < .001) and the number of taxane or platinum-based chemotherapy received (β = .21, p = .004). Two variables could account for 18% of the variances explained in CIPN among cancer patients treated with taxane and platinum-based chemotherapy (Adjust R2 = .18).
Conclusion and recommendations: Nurses and healthcare providers should closely assess factors influencing CIPN symptoms in cancer patients receiving taxane and platinum chemotherapy, including the number of taxane or platinum-based chemotherapy received and negative emotional states. Additionally, they should develop effective interventions to prevent and reduce negative emotional states to promptly manage CIPN symptoms and enhance patients’ quality of life.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Notice: Nursing Science Journal of Thailand has exclusive rights to publish and distribute the manuscript and all contents therein. Without the journal’s permission, the dissemination of the manuscript in another journal or online, and the reproduction of the manuscript for non-educational purpose are prohibited.
Disclaimer: The opinion expressed and figures provided in this journal, NSJT, are the sole responsibility of the authors. The editorial board bears no responsibility in this regard.
References
Mattar M, Umutoni F, Hassan MA, Wamburu MW, Turner R, Patton JS, et al. Chemotherapy-induced peripheral neuropathy: a recent update on pathophysiology and treatment. Life (Basel). 2024;14(8):991. doi: 10.3390/life14080991.
Srivastava SP, Sinha AP, Sharma KK, Malik PS. Severity, risk factors and quality of life of patients associated with chemotherapy-induced peripheral neuropathy. Clin Nurs Res. 2022;31(6):1080-90. doi: 10.1177/10547738221085613.
Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther. 2021;9(2):385-450. doi: 10.1007/s40487-021-00168-y.
Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, et al. Risk factors for chemotherapy- induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9(6):e01312. doi: 10.1002/brb3.1312.
Trendowski MR, Lusk CM, Ruterbusch JJ, Seaton R, Simon MS, Greenwald MK, et al. Chemotherapy-induced peripheral neuropathy in African American cancer survivors: risk factors and quality of life outcomes. Cancer Med. 2021;10(22):8151-61. doi: 10.1002/cam4.4328.
Thanakun P, Jitpanya C, Pudtong N. Relationships among body mass index, medicine, anxiety, depression, physical activity, and chemotherapy-induced peripheral neuropathy in patients with breast cancer. Journal of Health Science Boromarajonani College of Nursing Sunpasitthiprasong. 2021;5(1):53-67. (in Thai).
Kim M, Jung MS. Effects of chemotherapy-induced peripheral neuropathy in women with breast cancer: a structural equation approach with the Theory of Unpleasant Symptoms. Cancer Nurs. 2021;44(2):145-53. doi: 10.1097/ncc.0000000000000764.
Mizrahi, Park SB, Li T, Timmins HC, Trinh T, Au K, et al. Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy. JAMA Netw Open. 2021;4(2):e2036695. doi: 10.1001/jamanetworkopen.2020.36695.
Lemanska A, Harkin A, Iveson T, Kelly C, Saunders M, Faithfull S. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open. 2023;8(6):102063. doi: 10.1016/j.esmoop.2023.102063.
Jiwpanya S, Saneha C, Puwarawuttipanit W, Danchaivijitr P. Factors predicting chemotherapy induced peripheral neuropathy in breast cancer patients receiving neurotoxic chemotherapy. Chulalongkorn Medical Journal. 2021;65(2):155-63. doi: 10.58837/CHULA.CMJ.65.2.7.
Timmins HC, Li T, Goldstein D, Trinh T, Mizrahi D, Harrison M, et al. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. J Cancer Surviv. 2022;16(2):223-32. doi: 10.1007/s11764-021-01012-y.
Kleckner IR, Jusko TA, Culakova E, Chung K, Kleckner AS, Asare M, et al. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy. Breast Cancer Res Treat. 2021;189(2):521-32. doi: 10.21203/rs.3.rs-544812/v1.
Verhoeff-Jahja R, Ter Kuile MM, Weijl NI, Oosterkamp R, Cloos M, Portielje JEA, et al. Symptoms of anxiety but not depression before start of taxane-based chemotherapy are associated with peripheral neuropathy: a multicenter study in women with breast cancer. Supportive Care Cancer. 2022;30(8):6947-53. doi: 10.1007/s00520-022-07093-4.
Sabamnet S, Saneha J, Poungkaew A, Soparattanapaisan N. Predicting factors for chemotherapy-induced peripheral neuropathy in colorectal cancer patients undergoing chemotherapy. Journal of The Police Nurses. 2022;14(2):268-77. (in Thai).
Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci. 1997;19(3):14-27. doi: 10.1097/00012272-199703000-00003.
Roussea A, Geraud A, Geiss R, Farcet A, Spano J-P, Hamy A-S, et al. Safety of solid oncology drugs in older patients: a narrative review. ESMO Open. 2024;9(11):103965. doi: 10.1016/j.esmoop.2024.103965.
Ueno K, Kaneko H, Suzuki Y, Okada A, Fujiu K, Jo T, et al. Change in body mass index and cardiovascular outcomes in patients with cancer. Mayo Clin Proc. 2024;99(6):891-901. doi: 10.1016/j.mayocp.2024.02.003.
Wen H, Deng G, Shi X, Liu Z, Lin A, Cheng Q, et al. Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies. ESMO Open. 2024;9(3):102241. doi: 10.1016/j.esmoop.2024.102241.
Borson S, Scanlan JM, Chen P, Ganguli M. The mini-cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x.
Trongsakul S, Lambert R, Clark A, Wongpakaran N, Cross J. Development of the Thai version of Mini-Cog, a brief cognitive screening test. Geriatr Gerontol Int. 2015;15(5):594-600. doi: 10.1111/ggi.12318.
Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the beck depression and anxiety inventories. Behav Res Ther. 1995;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u.
Psychology Foundation of Australia. Depression Anxiety Stress Scales (DASS) [Internet]. Sydney: The Psychology Foundation of Australia; 2023 [cited 2023 Jul 20]. Available from: http://www2.psy.unsw.edu.au/groups/dass.
World Health Organization. Global recommendations on physical activity for health. Geneva: World Health Organization; 2010 [cited 2023 Mar 6]. Available from: https://iris.who.int/bitstream/handle/10665/44399/9789241599979_eng.pdf?sequence=1.
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135-9. doi: 10.1016/j.ejca.2005.02.012.
Prasertsri N, Kaewmanee C, Khantichitr P, Triyapan V, Lavoie SEM, Wamalun C, et al. Chemotherapy-induced peripheral neuropathy (CIPN): a cross-sectional study in cancer patients. Journal of Nursing and Health Research. 2017;18(3):52-62. (in Thai).
